Connection
David Camidge to Safety
This is a "connection" page, showing publications David Camidge has written about Safety.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.061 |
|
|
|
-
Camidge DR, Smethurst D, Growcott J, Barrass NC, Foster JR, Febbraro S, Swaisland H, Hughes A. A first-in-man phase I tolerability and pharmacokinetic study of the cyclin-dependent kinase-inhibitor AZD5438 in healthy male volunteers. Cancer Chemother Pharmacol. 2007 Aug; 60(3):391-8.
Score: 0.061